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Abstract
This article provides an educational review covering the consideration of conducting ‘value for money’ analyses as part of 
non-randomised study designs including service evaluations. These evaluations represent a vehicle for producing evidence 
such as value for money of a care intervention or service delivery model. Decision makers including charities and local and 
national governing bodies often rely on evidence from non-randomised data and service evaluations to inform their resource 
allocation decision-making. However, as randomised data obtained from randomised controlled trials are considered the 
‘gold standard’ for assessing causation, the use of this alternative vehicle for producing an evidence base requires careful 
consideration. We refer to value for money analyses, but relect on methods associated with economic evaluations as a form 
of analysis used to inform resource allocation decision-making alongside a inite budget. Not all forms of value for money 
analysis are considered a full economic evaluation with implications for the information provided to decision makers. The 
type of value for money analysis to be conducted requires considerations such as the outcome(s) of interest, study design, 
statistical methods to control for confounding and bias, and how to quantify and describe uncertainty and opportunity costs 
to decision makers in any resulting value for money estimates. Service evaluations as vehicles for producing evidence 
present diferent challenges to analysts than what is commonly associated with research, randomised controlled trials and 
health technology appraisals, requiring speciic study design and analytic considerations. This educational review describes 
and discusses these considerations, as overlooking them could afect the information provided to decision makers who may 
make an ‘ill-informed’ decision based on ‘poor’ or ‘inaccurate’ information with long-term implications. We make direct 
comparisons between randomised controlled trials relative to non-randomised data as vehicles for assessing causation; given 
‘gold standard’ randomised controlled trials have limitations. Although we use UK-based decision makers as examples, we 
relect on the needs of decision makers internationally for evidence-based decision-making speciic to resource allocation. 
We make recommendations based on the experiences of the authors in the UK, relecting on the wide variety of methods 
available, used as documented in the empirical literature. These methods may not have been fully considered relevant to 
non-randomised study designs and/or service evaluations, but could improve and aid the analysis conducted to inform the 
relevant value for money decision problem.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4027 3-020-00907 -5) contains 
supplementary material, which is available to authorized users.
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Key Points 
Service evaluations and associated evidence do not tend 
to receive the same peer-reviewed scrutiny, govern-
ing oversight, time or budgetary allowances relative 
to research as deined from a study ethics perspective. 
However, as a vehicle for producing evidence, the same 
rigorous methods that are associated with conducting 
research should be considered if permitted
Guidance and checklists exist for conducting economic 
evaluations alongside randomised controlled trials and 
as part of health technology assessments. However, as 
service evaluations usually serve a diferent purpose, 
useful and fundamental methods may be overlooked 
when assessing ‘value for money’
It is diicult to suggest a single method to produce the 
‘value for money’ evidence needed. However, evaluators 
need to consider the needs of the commissioner, but also 
what is required to produce the ‘best’ possible evidence 
(i.e. less uncertain and biased, but potentially costly) to 
inform the resource allocation decision problem
Evaluators should be transparent about the limitations 
of analyses that they conduct and should relect on the 
impact that choices in the methods used may have on the 
results, conclusions and recommendations
1 Introduction
A consensus exists that policy and clinical decisions that 
afect the public and individual patients should be evidence-
based [1, 2]. However, there is less clarity as to what con-
stitutes ‘appropriate’ economic or ‘value for money’ (VfM) 
evidence, by which resource-allocation decision-making can 
be informed. In many cases within healthcare, particularly 
health technology assessments (HTAs) of new and existing 
medicines and treatments [3], the primary source of evi-
dence may derive from research in the form of randomised 
controlled trials (RCTs). In the UK, these HTA processes 
are undertaken on behalf of the National Institute for Health 
and Care Excellence (NICE) and referred to as technology 
appraisals (TAs) [3]. NICE has inluenced international pro-
cesses, guidelines [4], and subsequently the HTA evidence 
base with Sculpher and Palmer [5] suggesting NICE could 
be considered a method innovator. Even before NICE’s inlu-
ence, internationally RCTs are often considered the ‘gold 
standard’ vehicle for producing evidence related to causation 
such as ‘treatment efects’ [6]. In this article, we argue that 
RCTs and research more broadly, here deined as an exercise 
designed to inform decisions with clearly deined questions, 
aims and objectives to provide generalisable results [7], rep-
resent a subset of the possible relevant evidence base for a 
given decision problem. Indeed, in many cases conducting 
RCTs to gather evidence may not be appropriate, practical, 
afordable, ethical or even possible [8, 9].
In this article, we focus on interventional studies as non-
randomised study designs including those conducted as 
service evaluations. From an ethics perspective, research 
is a vehicle for obtaining evidence with an ethical and 
underpinning legislative framework [7, 10]. As an alterna-
tive to research, service evaluations do not require research 
ethics (often referred to as ‘NHS ethics’ in the UK) [7]. 
Obtaining research ethics approval can be time consuming 
and may delay the start of a study [11]. Therefore, avoid-
ing research ethic processes can be perceived as desirable 
in some circumstances (e.g. in the case of tight time and 
budget restrictions). However, an associated restriction for 
service evaluations is random allocation to treatment options 
is not permitted [7]. Additionally, the use of routine data 
is encouraged for service evaluations relative to primary 
data collection [7]. Service evaluations are not intended to 
provide generalisable estimates of intervention eicacy or 
efectiveness relative to an existing intervention, but they 
may be the source of the best evidence available. Although 
internationally alternatives to ‘research’ might be called or 
deined diferently, evaluations that utilise non-randomised 
data are often used to inform decision-making such as by 
charities and local and national governing bodies [12, 13]. 
Non-randomised data and service evaluations present a dif-
ferent challenge to analysts than what is commonly asso-
ciated with research, RCTs and HTAs. These evaluations 
usually serve a diferent purpose and require speciic study 
design and analytic considerations. However, there are 
useful and fundamental methods associated with conduct-
ing research and HTA processes that can be appropriately 
applied if governing, time and budget restrictions allow.
This article provides an educational review of consid-
erations when conducting VfM analyses in non-randomised 
studies including service evaluations. In doing so, we often 
make direct comparisons to RCTs and research as the cur-
rent ‘gold standard’ to highlight relative strengths and 
weaknesses. We discuss to what extent there is a difer-
ence between ‘service evaluation’ and ‘research’ in terms 
of governing ethics and methodologies that could be used. 
We describe alternative methods for VfM analyses used 
depending on the resource allocation interests of the deci-
sion maker. Aspects to consider in terms of study design, 
statistical methods to control for confounding and bias, and 
how to quantify and describe uncertainty and opportunity 
costs to decision makers in any resulting VfM estimates are 
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also described. The possible implications of producing VfM 
evidence when these aforementioned aspects are not taken 
into account are a key point for discussion. We provide a 
range of references for further reading, including a glos-
sary of cross-referenced key terms and methods provided 
in Appendix S1 of the Electronic Supplementary Material 
(ESM). Therefore, this article should be used as a reference 
guide when generating VfM evidence from non-randomised 
data including service evaluations, rather than a technical 
document describing in detail speciic methodologies.
2  Evidence‑Based Healthcare 
Decision‑Making: Are Randomised 
Controlled Trials the Only Choice?
Randomised controlled trials are considered the ‘gold stand-
ard’ for producing an evidence base related to causation, but 
their limitations have been noted [13, 14]. Validity com-
parisons of the evidence generated from non-randomised 
studies and RCTs have dispelled many misperceptions of 
the former as a viable option for producing an evidence 
base for healthcare decision-making [12–15]. Although the 
controlled nature of RCTs is often what enables them to 
produce explanatory results and have high ‘internal’ valid-
ity [16, 17], moving to real-world decision-relevant settings 
may be considered to improve the relative ‘external’ validity 
of such results [13].
Decision makers such as charities and local and national 
governing bodies are unlikely to commission RCTs in part 
because of their associated time and inancial costs. In the 
UK, this includes Clinical Commissioning Groups (CCGs) 
who are clinician-led bodies responsible for commis-
sioning healthcare services within a local area. Since the 
UK’s Health and Social Care Act of 2012 [18], CCGs have 
become increasingly responsible for the health needs of their 
district of responsibility. Furthermore, in the UK, nation-
ally funded initiatives such as projects within the National 
Health Service (NHS) Test Beds programme [19] have 
relied on service evaluations to produce an evidence base 
on intervention efectiveness and VfM in localised areas. 
Although these are UK examples, the inancial sustainability 
of healthcare systems internationally is reliant on the careful 
management and commissioning of the plethora of services 
and interventions that are available for a variety of deci-
sion makers to fund. The role of regional and local decision 
makers is explicitly mentioned in the Helsinki Statement 
on Health in All Policies (HiAP) [20, 21]. This call upon 
governments worldwide states that “health authorities at all 
levels (national, regional, local) are key actors in promoting 
HiAP” (p. 17), which includes “building knowledge by pro-
viding evidence of success and lessons learnt” (p. 18) [21]. 
The limited ability of many decision makers internationally 
to generate high-quality evidence and analyses necessitates 
the use of appropriate and timely approaches to inform their 
decision-making based on an accurate and relevant evidence 
base. Internationally, few decision makers have the available 
inances to produce evidence such as the National Institute 
for Health Research (NIHR) as the largest national funder 
of clinical research in Europe [22]. As such, there has been 
much international interest in alternatives to RCTs to pro-
duce an evidence base including related to VfM [23].
3  Research and Service Evaluations: Why are 
They Used and is There a Diference?
In the UK, service evaluations are generally used when the 
intervention of interest has been, or is about to be, imple-
mented within a speciic care setting. Unlike research, ser-
vice evaluations are generally not based on well-formed aims 
and objectives to answer speciic hypotheses to produce 
generalisable results. Instead, they are used to assess ‘what 
standard does this service achieve’ in a more general sense, 
with aspects of interest often being related to efectiveness 
and/or VfM.
As an overview of our perspective when assessing 
VfM, we do not believe there is a clear dichotomy between 
research and service evaluation other than from an ethics 
perspective and associated legislative underpinnings. Even 
from an ethics perspective, this dichotomy is not always 
clear. What deines ‘research’ from an ethics perspective 
internationally is complex, with aspects for consideration 
described by Gevers [10] including the seminal Declara-
tion of Helsinki [24] for informing international human 
research ethics. From a UK perspective, Table 1 provides 
an overview of what the NHS Health Research Authority 
(HRA) Research Ethics Service (RES) considers ‘research’ 
relative to ‘service evaluation’. The HRA also has set stand-
ard operating procedures for Research Ethics Committees 
(RECs) to try and make processes more standardised and 
transparent including when judging what is ‘research’ [25]. 
A key point from Table 1 is that randomisation is only per-
mitted within research. Therefore, a key consideration for 
service evaluations is conducting analyses using non-ran-
domised data.
Suggesting what interventions can be evaluated within 
a ‘research’ ethics framework or otherwise (e.g. as a ser-
vice evaluation), in the UK or internationally, is outside 
the scope of this article. However an evaluation is deined 
ethically, when it comes to evaluating VfM, we suggest the 
same rigorous considerations are required. This includes 
when developing the study design (without purposeful or 
random allocation of the intervention for service evalua-
tions), analytical methods and reporting of evidence. We 
further discuss this perceived dichotomy between ‘research’ 
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Table 1  Deining service evaluations relative to research from UK Health Research Authority guidance.  Source: NHS HRA Research Ethics Service [7]
The text within this table has been directly quoted from the “Deining research” (Oct 2017) table developed by the National Health Service’s (NHS’s) Health Research Authority’s (HRA’s) 
Research Ethics Service [1]. Any mention of qualitative research in the original table has been omitted in the above table due to the fact value for money analysis is typically classiied as quanti-
tative analysis, and so qualitative analysis is not pertinent to the objectives of the manuscript
No Consideration Research Service evaluation
1 Overarching purpose “The attempt to derive generalisable or transferable new knowledge to answer 
questions with scientiically sound methods including studies that aim to gen-
erate hypotheses as well as studies that aim to test them, in addition to simply 
descriptive studies.”
“Designed and conducted solely to deine or judge current care.”
2 Study design “Quantitative research—can be designed to test a hypothesis as in a randomised 
controlled trial or can simply be descriptive as in a postal survey.”
“Designed to answer: “What standard does this service achieve?””
3 Study question “Quantitative research—addresses clearly deined questions, aims and objec-
tives.”
“Measures current service without reference to a standard.”
4 Intervention of interest “Quantitative research—may involve evaluating or comparing interventions, 
particularly new ones. However, some quantitative research such as descrip-
tive surveys, do not involve interventions.”
“Involves an intervention in use only. The choice of treatment, care or services 
is that of the care professional and patient/service user according to guidance, 
professional standards and/or patient/ service user preference.”
5 Intervention allocation “Quantitative research—study design may involve allocating patients/service 
users/healthy volunteers to an intervention.”
“No allocation to intervention: the care professional and patient/ service user 
have chosen intervention before service evaluation.”
6 Randomisation “May involve randomisation.” “No randomisation.”
7 Data collection “Usually involves collecting data that are additional to those for routine care 
but may include data collected routinely. May involve treatments, samples 
or investigations additional to routine care. May involve data collected from 
interviews, focus groups and/or observation.”
“Usually involves analysis of existing data but may also include administration of 
interview(s) or questionnaire(s).”
8 Research Ethics Com-
mittee (REC) review
“Normally requires REC review but not always.” “Does not require REC review.”
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and ‘service evaluation’ from a UK perspective with some 
international considerations in Appendix S2 of the ESM.
4  Economic Evaluations and Partial 
Evaluations: Methods and Distinctions
Economic evaluation is widely used for the appraisal of 
healthcare programmes, taking into account both the costs 
and the consequences (i.e. efects or outcomes) of two (or 
more) alternatives [26]. There are multiple forms of eco-
nomic evaluation. However, all are VfM analyses, with 
‘costs’ representing an integral aspect of the evaluation 
process owing to the resultant opportunity costs (Appendix 
S1 of the ESM) from resources not being available for other 
purposes [27–29]. Traditionally, at the local level, there 
has been very little use of economic evaluation evidence, 
although there is suggestion this has increased overtime par-
ticularly in the UK [30, 31]. There is a need to explain and 
rationalise the purpose of economic evaluation to decision 
makers with a particular focus on commissioners of the eval-
uation and decision makers they represent. A commissioner 
is an individual (or group) who has a legitimate authority to 
make decisions, such as a representative of a local governing 
body being put in charge of identifying relevant experts to 
conduct the VfM analyses (e.g. health economists). From 
a commissioning perspective, requesting a VfM analysis 
may be more pertinent than requesting an economic evalu-
ation. The term ‘value for money’ tends to mean something 
to commissioners more than ‘economic evaluation’, partly 
because it is a politically motivated and widely recognised 
term. The NHS Constitution for England states: “The NHS 
is committed to providing best value for taxpayers’ money” 
[32]. Thus, making ‘value for money’ a political ‘buzz word’ 
when discussing care funding and provision.
In the UK, cost-efectiveness analysis (CEA) in the form 
of cost-utility-analysis (CUA) based on quality-adjusted 
life years (QALYs) has become the most popular form of 
economic evaluation. This is partly because it is NICE’s 
‘gold standard’ reference case, with NICE’s guidelines [3] 
informing HTA processes internationally [4]. There are sev-
eral papers debating the extent that economic evaluations 
of diferent forms of interventions it a typical HTA [33, 
34], such that current guidelines may not be fully applica-
ble, including: public health [35–37], antimicrobials [38], 
diagnostics [39], medical devices [40], genetics [41], digital 
[42], environmental [43], and service and delivery interven-
tions [33, 44]. Whatever the intervention of interest, Drum-
mond et al. [26] suggest that an economic evaluation would 
“explicitly consider the relative consequences of the alterna-
tives and compare them with the relative costs” (p. 5). Any-
thing else than the aforementioned “economic evaluation” 
is a “partial evaluation” (see Table 2).
Common economic evaluation methods include cost–ben-
eit analysis (CBA), which uses individuals’ values for their 
outcomes to convert into a monetary unit, and CEA/CUA, 
which values outcome in natural units (usually health out-
comes that for CUA are preference-based) [26]. Each of the 
aforementioned tend to represent VfM as a single outcome, 
normally as a ratio of outcomes relative to costs, e.g. incre-
mental cost-efectiveness ratios (ICERs) and beneit–cost 
ratios (the equations for these ratios are presented in Appen-
dix S3 of the ESM). Alternative economic evaluation meth-
ods include cost-minimisation analysis (CMA) and cost-
consequence analysis (CCA). Cost-minimisation analysis is 
considered lawed based on its underlying assumption that 
outcomes can be equivalent between alternatives [26, 45] (a 
review on using CMA to inform NICE is underway [46]). 
Cost-consequence analysis ofers lexibility for representing 
VfM in a disaggregated or aggregated manner [47–50], but 
using a single outcome for cross-comparison decision-mak-
ing has comparative advantages and disadvantages [51, 52]. 
Budget impact analysis (BIA) [48, 53] is a ‘partial evalua-
tion’ method that only accounts for costs to addresses the 
expected changes in the expenditure of a healthcare system 
after the adoption of a new intervention [48]. Budget impact 
analysis is recommended to be included alongside economic 
evaluation methods such as CEA [48] and CCA [54, 55].
Other cost-related methods used within service evalua-
tions, commonly associated with evaluating public health 
programmes [56], include return on investment (ROI) analy-
sis often based on cost savings as the ‘return’ (thus a par-
tial evaluation) [57, 58] and social ROI analysis based on 
natural outcomes given monetary weights [59–61]. Whether 
social ROI analyses can be considered a full economic rela-
tive to partial evaluation depends on what costs are taken 
Table 2  Overview of types of analysis focussed on costs and consequences.  Source: Adapted from Drummond, Sculpher [26]
*Consequences can be referred to as ‘beneits’ or ‘outcomes’, noting that ‘efect’ implies causality. These consequences are the impact on people 
or a population in terms of health or ‘welfare’; although, well-being is of growing concern for economic evaluations
** Costs often include cost beyond intervention costs (e.g. treatment costs) dependent on the costing perspective (see Sect. 5)
Options for analysis Examine only consequences* Examine only costs** Examine consequences and costs
No comparison of alternatives Outcome description Cost description Cost-outcome evaluation
Comparison of alternatives Eicacy or efectiveness evaluation Cost-comparison analysis Economic evaluation
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into account and if there is a comparison with an alternative 
(which are also factors for consideration with ROI analyses, 
with Sect. 5 including a relevant discussion related to costs). 
Often there is confusion between evaluation approaches 
because of how outcomes are presented to decision makers. 
However, certain approaches may contain the same informa-
tion, but with a diferent presented outcome, e.g. as an ICER 
rather than a beneit–cost ratio (Appendix S3 of the ESM 
further discusses this aspect).
5  Costing Perspective: Intervention Costs, 
Future Costs and Other Considerations
The costs to include in a VfM analysis are dependent on 
what question needs to be answered for the decision con-
text being informed [26, 28, 62]. Fundamentally, when a 
care service introduces an intervention or delivery model, 
the evaluation should include the direct costs of this aspect 
referred to as ‘intervention costs’ (Appendix S1 of the ESM). 
For example, if a new member of staf was introduced within 
a care system, the cost of this staf member over the time 
horizon of interest should be included. When comparing 
between two alternatives, incremental costs associated with 
the intervention relative to the alternative(s) assessed (e.g. 
usual or previous care model) are of interest. These direct 
intervention costs should always be included in the VfM 
analysis. However, what other costs should be included is 
the focus of considerable debate and research. de Vries et al. 
[63] have attempted to classify potential other costs into 
three categories, each described as ‘future costs’ (Appendix 
S1 of the ESM): (1) future related medical costs; (2) future 
unrelated medical costs; and (3) future non-medical costs. de 
Vries et al. [63] state that the literature suggests that inclu-
sion of ‘related’ and ‘unrelated’ medical costs is required 
to obtain optimal outcomes from available resources irre-
spective of the costing perspective adopted. The inclusion 
of medical costs is referred to as the care-payer perspective 
(Appendix S1 of the ESM). However, ‘unrelated’ costs are 
typically diicult to deine and thus often excluded/ignored 
[64, 65]. A case for also collecting non-medical costs as part 
of a societal perspective (Appendix S1 of the ESM) has been 
made by Jönsson [66]. A framework for including the soci-
etal perspective and associated complications is described 
by Walker et al. [67].
Obtaining future cost data can be costly, timely and 
resource intensive (depending on if data are readily available 
or not) [68]. As such for service evaluations, what future 
costs are included alongside the intervention costs may be 
limited to where beneits could be observed rather than 
accounting for opportunity costs across the wider care sys-
tem. This may be more pertinent with ROI analyses, which 
often focusses just on intervention costs relative to beneicial 
returns without accounting for wider cost implications. For 
example, introducing set ‘inpatient bed days’ could reduce 
short-term hospital costs, which in a ROI analysis could 
seem beneicial, but this ignores wider morbidity, mortal-
ity, readmission and care costs associated with discharging 
patients too early. It seems reasonable to suggest that a full 
economic evaluation should attempt to account for future 
costs over an appropriate time horizon to capture resource 
use implications of the intervention of interest. The exact 
future costs to include have yet to be irmly established and 
thus may be informed by the decision maker’s perspective 
with potential implications for the evaluation (see Sect. 9). 
In some cases, there is also a suggestion to include ‘imple-
mentation’ costs, such that timely implementation of recom-
mended interventions can provide health beneits to patients 
and cost savings to health service providers [69]. There are 
debates and complications with the inclusion of such costs 
[69–71], with a discussion on the economic evaluation of 
implementation strategies in healthcare by Hoomans and 
Severens [72].
6  Routine Data for Estimating Resource Use, 
Costs and Non‑monetary Consequences
Primary data collection can be time consuming and costly, 
but may also have implications that consider ethical consid-
eration (e.g. if talking to vulnerable groups). As such, for 
service evaluations using routinely collected data is recom-
mended [7]. The data available for analysis may restrict the 
VfM method (Sect. 4) and costing perspective (Sect. 5), but 
could also inform the potential study design (Sect. 7).
Cost data for VfM analyses are estimated based on care 
resource-use data to which unit costs are attached (Appendix 
S1 of the ESM) [28]. There are self-reported and routinely 
collected resource-use data methods as described by Frank-
lin and Thorn [68], noting their (and our) examples are based 
on routine data sources in England. If the consequences of 
interest are also related to resource use (e.g. cost per inpa-
tient bed days avoided), then the source of routine data for 
costs and consequences may be the same. The range of 
resource-use information required will depend on the cost-
ing perspective (Sect. 5). However, diferent care services 
tend to collect their resource-use information on diferent 
electronic systems, which often do not tend to be linked at 
the patient or service level (e.g. primary care and hospital 
care) [68]. Although large linked databases may exist, their 
use has complications [68, 73]. In England, commissioners 
can supplement their local data lows with data from the 
Secondary Uses Service (SUS) [74]. Such data could be 
used for service evaluations, albeit with a variety of time, 
monetary, technical and information governance restrictions 
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[68]. As such, routine data are recommended but often dif-
icult to utilise [28, 68, 75].
For CEA, consequences are measured in natural units that 
could be based on routinely collected data (e.g. ‘cost per 
death avoided’ based on mortality data). For CUA, prefer-
ence-based values for health-related outcomes are required 
to elicit the QALY (Appendix S1 of the ESM) [3]. Obtain-
ing such preference-based values can be problematic if not 
routinely collected (e.g. routinely collecting the EQ-5D, 
as the NICE-preferred preference-based measure [3]). As 
an example of using indirectly collected preference-based 
data, Franklin et al. [76] suggest a method for attaching 
preference-based values to routinely collected, health-related 
events of interest (i.e. asthma exacerbations) to conduct a 
CUA. Preference-based values, often referred to as ‘utility’ 
values, could be sourced via the ScHARR Health Utilities 
Database (ScHARRHUD [77]: www.schar rhud.org). If clini-
cal or condition-speciic measures relevant to the interven-
tion of interest are routinely collected which could be used 
for CEA, then a ‘mapping’ or ‘cross-walk’ algorithm may 
exist to allow the statistical prediction of utility values from 
that measure to conduct CUA. The purpose and procedures 
of statistical mapping are described by Longworth and 
Rowen [78], with a systematic review of mapping studies 
by Mukuria et al. [79], and an online database of mapping 
studies also currently available (HERC database of mapping 
studies [80]: www.herc.ox.ac.uk/downl oads/herc-datab ase-
of-mappi ng-studi es).
7  Statistical Considerations Based on Study 
Design, Underlying Data Attributes, 
and for Reporting Uncertainty
The desired form of VfM analysis should be accounted for 
at the study design stage, given that not all study designs are 
good vehicles for VfM analyses [26]. When time and inance 
are restricted, the study design might be dependent on data 
availability (Sect. 6). Value for money analyses are ‘analyti-
cal’ in nature because there is an intention to infer VfM as a 
causal factor related to an intervention compared to an alter-
native (e.g. usual or previous care model). As such, there 
will be the need to choose an analytical study design and 
associated appropriate statistical method(s). Hinde et al. [81] 
have explored the possible scenarios that could occur when 
seeking to conduct a quantitative evaluation of an interven-
tion at the local level, speciically with regard to availability 
of evidence, the subsequent statistical method chosen and 
the resulting impact on ‘efectiveness’ evidence.
Analytic study designs as required for VfM analyses 
can be broadly classiied as observational (e.g. case series, 
cohort, cross-sectional and case–control study designs [82, 
83]), or experimental (e.g. before-and-after studies [84, 
85], comparative/controlled trials and RCTs [82]). These 
are diferent to ‘descriptive’ studies, which could include 
describing costs, qualitative studies or cross-sectional sur-
veys [86]. In analytic studies, participants are identiied 
and observed, and characteristics including outcomes and 
costs are recorded. Additionally, for experimental studies, 
the setting should be equivalent across all participants, an 
intervention is used and is part of the assessment and there 
is an observation/evaluation of the efects of the interven-
tion with causality being of particular interest (relative to 
association as a common interest in observational studies). 
When causality is of particular interest, there is a need to 
reduce chance, eliminate bias and account for confounding 
(Appendix S1 of the ESM). Although these aspects can be 
accounted for using statistical methods, good study designs 
reduce reliance on statistical methods with experimental 
studies generally regarded as being less susceptible to bias 
than observational studies.
Experimental designs such as comparative trials are 
generally preferred when inferring causality, with a pref-
erence for randomised trials [82]. Randomisation to treat-
ment groups is preferred as the process reduces chance and 
bias in resulting study estimates, but RCTs themselves have 
limitations [13, 14]. In any case, randomisation to treatment 
groups is not ethically permitted outside of research (see 
Table 1 for a UK perspective). Therefore, non-randomised 
and historical control designs may be options for service 
evaluations. Historical controls alone have been shown to 
overestimate new treatment beneits [85, 87]. Authors such 
as Goodacre [84] have made a case why before-and-after 
studies without a comparison group and/or appropriate sta-
tistical methodology (e.g. interrupted time-series analysis, 
described later in this section) should be discouraged for 
evaluations. For non-randomised comparative trials (sup-
plemented with or without historical data for both groups) 
particularly as part of a service evaluation, there are often 
diiculties when trying to recruit and perform primary data 
collection for a control group (or obtain relevant and neces-
sary historical data retrospectively). Primary data collection 
and recruitment is expensive, time consuming, may have 
ethical considerations, and is thus often deemed undesirable 
by the service evaluation funder. Service evaluations could 
be conducted as ‘natural experiments’. Natural experiments 
are deined as: “naturally occurring circumstances in which 
subsets of a population have diferent level of exposure to a 
supposed causal factor, in a situation resembling an actual 
experiment where human subjects would be randomly allo-
cated to groups” [88, 89]. Deidda et al. [88] have devel-
oped an economic evaluation framework when using natural 
experiments with a speciic focus on public health interven-
tions. As the framework was developed mainly to evaluate 
public health interventions, not all aspects of the framework 
may be relevant nor necessary for all service evaluations. For 
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example, under ‘costs’, the framework suggests a societal 
perspective would be of interest; however, such a perspec-
tive may not be required/possible for all interventions to be 
evaluated (Sect. 5).
When economic evaluations are conducted as part of 
non-randomised study designs, the need to account for the 
non-randomised nature of the data is not always recognised 
[23]. There are suggested statistical methods/guidance to 
mitigate confounding and bias using observational [90] and 
‘real-world’ data [91]. As an example, guidance by Faria 
et al. [90] provides an overview of a method described as 
‘Matching’, which aims to replicate randomisation by iden-
tifying/matching control individuals who are similar to 
those receiving the intervention in one or more characteris-
tic. Matching could be conducted within routinely collected 
datasets, assuming enough patient characteristics exist for 
matching, and subsequently used for the VfM analysis as 
part of a service evaluation (Sect. 6). There has been much 
interest in how such methods can be applied to improve VfM 
analyses (particularly CEA) using non-randomised data. As 
examples, using propensity score matching methods for 
CEAs has been explored by Manca and Austin [92]. Using 
regression-adjusted matching and double-robust methods 
for estimating average treatment efects in health economic 
evaluations has been explored by Kreif et al. [93]. The use 
of propensity score matching against other methods used 
in observational data such as diference-in-diference and 
regression models for (health) economic analysis has been 
explored by Crown [94]. Guidance on choosing an appro-
priate weighting mechanism for propensity score matching 
is described by Desai and Franklin [95]. These ‘matching’ 
methods are useful when there is interest in better dein-
ing a group for comparison to reduce bias. In comparison, 
interrupted time-series analysis, a statistical method using 
longitudinal data, has been preferred for single-arm before-
and-after studies without a comparator [84] and has been 
used to inform modelling-based (Appendix S1 of the ESM) 
economic evaluations [96]. A short tutorial for using inter-
rupted time-series to evaluate public health interventions 
is described by Bernal et al. [97], which outlines the data 
needed for interrupted time-series analyses. How to com-
bine statistical methods that account for the non-randomised 
aspects of the data among other considerations pertinent to 
VfM analyses (e.g. comparison between alternatives, and 
accounting for costs and outcomes) is still an area for further 
research and guidance.
There are speciic statistical considerations pertinent to 
VfM analyses that need to be accounted for alongside the 
non-randomised nature of the data. Two educational reviews 
already describe the use of utility data for CUA [98] and 
costs for CEA [28], both of which describe statistical con-
siderations such as: assessing cost and consequence (util-
ity) data and its distribution; baseline covariate adjustments; 
and dealing with missing data. We do not wish to repeat 
these educational reviews. Instead, we shall summarise a 
few key points and suggested statistical methods, focussing 
particularly on costs as a common factor in all VfM anal-
yses. Controlling for baseline covariates (i.e. aspects that 
inluence costs, e.g. age, frailty, health status) is a simple 
method for making adjustments to improve precision and 
correct for between-group imbalances [99], particularly for 
non-randomised groups. Regression-based methods are typi-
cally used to account for baseline covariates when making 
estimations. In the case of costs, the case has been made to 
use [28]: (1) parametric methods including ordinary least 
squares (OLS), generalised linear models (GLMs), extended 
estimating equations (EEE), multi-level models and gener-
alised estimating equations (GEE) models; and (2) non-par-
ametric methods including bootstrapping and the two-stage 
bootstrap. All forms of VfM should include unadjusted (i.e. 
observed) and adjusted analyses [28]. Although such meth-
ods have long been used as part of statistical analyses related 
to clinical outcomes [99], their use for VfM analyses has not 
always been fully recognised [28, 98].
There are also statistical methods that allow a better 
relection of the uncertainty around estimates, which should 
be applied to costs and consequences. Common methods 
applied to economic evaluations include bootstrapping for 
within-trial evaluations and probabilistic sensitivity analysis 
(PSA) using Monte Carlo simulation for modelling-based 
analyses (Appendix S1 of the ESM). These methods allow 
the random resampling of the observed data over a speciied 
number of iterations either non-parametrically or parametri-
cally. The estimates from which can be presented to decision 
makers in cost-efectiveness planes and cost-efectiveness 
acceptability curves (CEACs) to indicate the probability 
of achieving a speciied outcome over a range of monetary 
valuations of consequence outcomes [100], e.g. ‘cost-efec-
tiveness thresholds’ [101, 102]. An alternative that allows for 
a quantiication of a change in parameter(s) value if we are 
particularly unsure about point estimate value(s) is one- or 
multi-way sensitivity analyses, whereby point-estimate input 
values are changed (e.g. average intervention cost) and the 
resulting change in the outcome is reported (e.g. change in 
ICER value). An overview of the application of these meth-
ods to costs is described by Franklin et al. [28]. The use of 
such methods should be applied irrespective of the type of 
VfM analysis conducted, as they represent statistical meth-
ods to quantify and account for the uncertainty around the 
parameters associated with the VfM analyses that should be 
presented to decision makers.
Another aspect for consideration is using a relevant and 
appropriate time horizon. For service evaluations, particu-
larly if informing policy decisions that require timely evi-
dence, the ability to collect primary data over a relevant time 
horizon (whereby ‘relevant’ is dependent on the decision 
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context) is potentially limited. There are various methods for 
extrapolating results beyond an observed time horizon, such 
as survival analysis [103] and other methods to account for 
censoring [104–106] dependent on the parameter of interest 
(e.g. longer-term mortality or costs). Economic modelling 
is often rationalised based on the inability to collect suf-
icient parameter information over a relevant time horizon 
within a single study to inform the decision problem and 
thus could be an alternative option [107]. However, model-
ling analyses and subsequent estimates will be driven by the 
data used to inform the model, e.g. a key model driver will 
be the input parameter estimate of intervention treatment 
efectiveness. If the intention is to use a service evaluation 
to produce the estimates on treatment efectiveness that will 
drive the model, then the aforementioned statistical methods 
described in this section will still be needed when estimating 
treatment efects from non-randomised data. Examples of 
CUA modelling studies born of a service evaluation include 
Franklin and Hunter [108] (fall-screening and fall-prevention 
intervention) and Hunter et al. [109] (major system change 
in acute stroke services). It should be noted, however, some 
decision makers may be interested in short-term costs and 
consequences (monetary or otherwise). For example, over 
1 year because of yearly budget allocations (often associated 
with the ‘inancial year’), rather than long-term planning 
dependent on the decision problem (see Sect. 9).
8  Quantifying the Value of Information
As stated by Sculpher, Claxton [9]: “It is argued that any 
framework for economic analysis can only be judged insofar 
as it can inform two key decisions and be consistent with 
the objectives of a health care system subject to its resource 
constraints. The two decisions are, irstly, whether to adopt 
a health technology given existing evidence and, secondly, 
an assessment of whether more evidence is required to sup-
port this decision in the future”. The methods described in 
this article so far relate to the aforementioned irst point, 
but value of information (VOI) [Appendix S1 of the ESM] 
is associated with the second point. Value of information 
represents the monetary value of collecting more informa-
tion that could inform an investment decision. There are 
three types of VOI worth considering: expected value of 
perfect information (EVPI), expected value of partial perfect 
information (EVPPI) and expected value of sample informa-
tion (EVSI). An overview of these methods is described by 
Jackson et al. [110], with simpliied descriptions provided 
in Appendix S1 of the ESM.
There are two key issues with VOI in general and speciic 
to service evaluations. First, traditionally, VOI analyses are 
computationally complicated and time consuming. However, 
there are suggested methods [111–113] and free-licence 
software (e.g. Sheield Accelerated Value of Information 
tool [112]: https ://savi.shef.ac.uk/SAVI/) that can speed up 
and simplify the process, with a practical VOI guide by Wil-
son [114] and a description of emerging good practice VOI 
analytical methods by Rothery et al. [115]. Furthermore, 
although you need the output from a PSA or other Bayes-
ian framework to be able to calculate VOI [111], parameter 
values from within-study VfM analyses can be placed within 
a simple model (e.g. decision tree) to run a PSA and subse-
quent VOI analysis (Appendix S1 of the ESM) [116]. The 
second issue is related to understanding the outputs from 
VOI, explaining the implications to decision makers and 
why they should pay attention to VOI. For trials, VOI can 
be particularly useful for pilot and feasibility studies, as they 
will place a monetary value on the worth of conducting the 
next stage trial design (e.g. RCT). When informing local 
or national decision makers, the purpose is to highlight the 
potential monetary consequence of beginning or continuing 
to invest in an intervention based on the current information 
available. As stated in Sect. 3: “service evaluations are gen-
erally used when the intervention of interest has been, or is 
about to be, implemented within a speciic care setting”. As 
the decision maker may have already made the investment 
in an intervention, point estimates from any VfM analysis 
should conirm the already made decision to invest or not. 
However, such point estimates do not suggest if the service 
evaluation has provided enough information to inform the 
decision to invest in the future for as long as the investment 
decision is relevant (e.g. over the next 1–5 years). In addi-
tion, as many decision makers are responsible for a plethora 
of care interventions, another consideration is which inter-
ventions should be the focus of further evaluation in the 
future to check on their investment. Value of information 
can help prioritise and monetarise the investment in the ser-
vice evaluation as well as the investment in the intervention. 
Decision makers may not be able to fully comprehend the 
impact of investing in an intervention or service evaluation 
based on the information provided to them, particularly 
related to the uncertainty around estimates. Value of infor-
mation can quantify this aspect into a monetary value to be 
considered alongside other evidence provided.
9  Informing Decisions in Healthcare: 
A Discussion Related to Value for Money
Within this article, we have described a variety of matters 
to consider when conducting VfM analyses alongside non-
randomised study designs including service evaluations. 
Relecting on the UK, NICE has issued guidance on how 
to conduct economic evaluations for HTAs that were devel-
oped with allocative eiciency in mind across the whole 
NHS [3]. NICE’s processes and guidelines have inluenced 
 M. Franklin et al.
reimbursement agencies internationally speciic to their 
HTA processes [4, 5]. However, such guidelines have been 
described to not always be practical nor relevant in every 
decision-making context [33, 35–44]. Such guidelines may 
also align more with research practices than service evalua-
tions, whereby the former could include conducting expen-
sive RCTs whereas the latter may be a more ‘budget and 
time’ conscious approach. There may be a need to move 
away from guidelines such as NICE’s HTA processes as the 
‘gold standard’ for evaluating care interventions, but careful 
consideration and rationale need to be given when moving 
away from ‘gold standards’. This includes moving away from 
RCTs that dominant the HTA evidence base and CUA pre-
ferred by many reimbursement agencies internationally [4].
There are key diferences between producing evidence 
for a reimbursement agency like NICE compared to deci-
sion makers that are part of government. For example, in the 
UK, NICE currently acts as an independent reimbursement 
agency for the NHS (although it was once a special health 
authority for the NHS), is not part of any government body, 
and NICE’s evidence review groups (as an external academic 
organisation independent of NICE) review the evidence that 
informs the HTA process [117, 118]. NICE also has princi-
ples [119] that align with the NHS Constitution [32], which 
is to provide “the best value for taxpayers’ money and the 
most efective, fair and sustainable use of inite resources” 
(NICE principle 7, point 22) [119]. NICE’s principle when 
rationalising its stance on cost per QALY states as part of 
its allocative eiciency objective: “[Cost per QALY] takes 
into account the ‘opportunity cost’ of recommending one 
intervention instead of another, highlighting that there would 
have been other potential uses of the resource. It includes 
the needs of other people using services now or in the future 
who are not known and not represented” (NICE principle 
7, point 23) [119]. NICE has incorporated a level of inde-
pendence between the evidence reviewers and inal decision 
makers, while also producing guidance that aligns with its 
allocative eiciency objectives. In contrast, when producing 
evidence for local and national governing bodies, the deci-
sion maker may also be the commissioner of the evaluation, 
may have a narrower perspective when assessing ‘oppor-
tunity costs’ and a shorter time horizon of interest for the 
evaluation. Each of the aforementioned may not be good 
factors. The role of local relative to national government 
when providing healthcare has long been a point of debate 
internationally, with the World Health Organization relect-
ing on localised decision-making in their 1997 report “The 
role of local government in health: comparative experiences 
and major issues” [120]. More recently and focussed on the 
NHS, a question has been raised of “should local govern-
ment run the NHS?” [121], which aligns with the powers 
given to local agencies within the Health and Social Care 
Act of 2012 [18]. The advantages for local government made 
by Furber [121] mainly focus on local government’s ability 
to deal with localised public health concerns and inequality 
issues, relative to national concerns including opportunity 
costs across the whole NHS budget. From a sceptic’s per-
spective, the extent to which obtaining good-quality unbi-
ased estimates for a relevant time horizon is desirable rela-
tive to conirming an investment was ‘correct’ and wanting 
evidence to conirm this aspect can represent the diferent 
desires of local government agencies [122]. Additionally, 
as an example, localised decision makers may only wish to 
focus only on the opportunity costs in their jurisdiction of 
interest. For example, in England, an NHS foundation trust 
may only want to focus on care provided in hospitals as their 
care jurisdiction of interest. As such, their costing perspec-
tive may ignore other care services within which opportunity 
costs might be observed (e.g. primary care). Such decision 
makers may therefore opt to ignore other relevant oppor-
tunity costs that are recommended to be included by inde-
pendent reimbursement agencies such as NICE. There is a 
case to be made that focussing just on the decision makers’ 
perspective may not always be the appropriate perspective 
to take if, on the whole, it may lead to ineicient resource 
allocation across the whole care budget.
Based on NICE and other international reimbursement 
agencies’ guidance, CUA is preferred for HTA [3, 4]. A key 
rationale for using CUA is it allows for comparable outputs 
in terms of economic evidence (i.e. cost per QALY esti-
mates) for cross-care decision-making. Although the QALY 
framework is not perfect with a key debate questioning the 
concept of ‘a QALY is a QALY’, which enables cross-com-
parability [123, 124], using a single outcome metric such 
as the QALY still has its advantages albeit with the need 
for some suggested improvements [26, 125]. Using CUA is 
not restricted within service evaluations. Given the advan-
tages of using a single metric and the stance of many reim-
bursement agencies internationally, perhaps cost per QALY 
analysis should be given priority across all care resource-use 
decision-making (noting we make this case with a UK per-
spective speciically in mind). However, it should be noted 
that this perspective might difer dependent on the care 
funding system incorporated including the use of social and 
private health insurance systems, rather than a tax-based sys-
tem mainly used for the NHS. There has also been attempts 
and/or suggested frameworks to make CEA and QALYs 
applicable to more decision-making contexts. For example, 
equity concerns that are a key factor for consideration by 
many decision makers are suggested to be accounted for 
within distributional CEA for which there is a published 
tutorial [126], with a case study related to the UK Bowel 
Cancer Screening programme [127] and rotavirus vaccina-
tion programme in Ethiopia [128]. Furthermore, methods 
associated with estimating a new evidence-based cost-
efectiveness threshold for NICE [27] (relative to NICE’s 
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current non-evidence-based £20,000–£30,000 per QALY 
threshold [3]) has sprouted a range of other studies, debate 
[129–131] and associated methods for making CEA applica-
ble to more healthcare decision-making contexts. For those 
unaware of cost-efectiveness thresholds, McCabe et al. 
[102] (speciic to NICE) and Culyer [101] (more general 
concept) outline what they are and their uses. These methods 
for estimating cost-efectiveness thresholds are based on the 
concept of health opportunity costs, i.e. the health beneits 
that could have been achieved had the resources been used 
elsewhere in the healthcare system [132]. These methods 
incorporate wider opportunity cost concerns within CEA, 
QALYs and even disability-adjusted life years for use in low- 
and middle-income countries [133]. New approaches born 
from these methods include estimating social variation in 
the health efects of changes in healthcare expenditure [134]. 
Relatedly, Lomas [135] suggests a framework for incorporat-
ing afordability concerns alongside cost-efectiveness esti-
mates highlighting an example that using a BIA alongside a 
CEA does not deal with such concerns. The “cost-efective 
but unafordable paradox” [132] has been discussed in prior-
ity setting for global health programmes [136] but also in the 
context of high-income countries (e.g. UK and USA) [137, 
138], which has relevance for local and national decision 
makers with inite budgets.
Despite the case for using a single metric and advances 
made in its potential use (with limitations), cost per QALY 
is rarely used within service evaluations. We suggest two 
key reasons: (1) the study design and data collection meth-
odology means it is too diicult or not possible to collect 
the data to inform the CUA or (2) the CUA is not of inter-
est to the decision maker for various reasons, including not 
understanding how to interpret QALY gains and associated 
ICERs. Detsky and Laupacis [139], in their paper ‘Relevance 
of Cost-efectiveness Analysis to Clinicians and Policy Mak-
ers’, suggest that: “In addition to the problems of looking 
at cost-efectiveness ratios individually, interpreting those 
ratios can be di cult for clinicians and decision-makers. It is 
not easy to understand what a QALY is” (p. 223). How best 
to explain the QALY including how it is (or could be) used 
to inform decision-making is certainly an area of interest. 
An HTA report on ‘The use of economic evaluations in NHS 
decision-making’ by Williams et al. [51] suggests: “Com-
mittee [including local] members raised concerns about lack 
of understanding of the economic analysis but felt that a 
single measure of beneit, e.g. the quality-adjusted life-year, 
was useful in allowing comparison of disparate health inter-
ventions and in providing a benchmark for later decisions” 
(p. iii). This report suggests the QALY could have a place 
in local decision-making if stakeholders better understood 
its construct and purpose. Within a service evaluation con-
text, there is no guidance to suggest you have to, or how to, 
conduct a CUA, meaning it can be overlooked or avoided for 
the right or wrong reasons.
For service evaluations, if CUA is not desirable and/or 
possible, then other forms of VfM analyses may ofer poten-
tial alternatives. Arguably, producing any form of economic 
evidence to inform decision-making is better than no evi-
dence, provided the analysis and outcomes have been con-
ducted and reported ‘appropriately’ (e.g. appropriate study 
design, statistical analysis, and uncertainty and opportunity 
cost reporting options). An issue seems to stem from the 
lack of guidance and monitoring of the use of VfM analyses 
when informing localised and even national decision-making 
as part of service evaluations, which is more common for 
research. For example, NICE’s evidence review groups pro-
vide independent reviews of evidence used to inform deci-
sion-making [117, 118], and the NIHR has an independent 
peer-review process pre-funding and at the reporting stage 
associated with its funding programme journals [140]. Evi-
dence used by some decision makers and associated methods 
may not be properly peer reviewed, thus allowing for com-
missioners and decision makers to base their decisions on 
a multitude of evidence with varying quality. It should be 
noted that such peer-review processes themselves can be 
time consuming and costly, and thus may not be a practi-
cal nor cost-eicient option. However, the use of checklists 
such as Drummond et al. [26] and the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) [141] 
checklists still have a place alongside VfM for service evalu-
ations, as these standards should still enable cross-compara-
ble evaluations with some suggested/recommended methods 
included.
There are practical examples as part of the debate for 
[142] (here focussed on the Cancer Drugs Fund) and against 
[143] using RCTs, the ‘against’ here being a comedic look 
at using RCTs to assess parachute use to prevent death 
and major trauma when jumping from aircraft. The use of 
RCTs is debated relative to other options including non-
randomised, real-world, and observational data either with 
or without a comparison group, and using historical controls 
[13]. Further work should be conducted on how VfM meth-
odology can be adapted to deal with these diferent study 
designs and data sources. For example, an economic model 
by Franklin et al. [96] combined treatment efect evidence 
from an interrupted time-series analysis using routine data 
with modelling methodology to conduct a CUA. Although 
this example represents one potential solution and relied on 
a natural experiment design to conduct the interrupted time-
series analysis, further work is required to examine how to 
combine existing statistical methods for determining treat-
ment efects in observational [90] and real-world [91] data 
with VfM methodology.
Multi-criteria decision-making (MCDM)  and multi-
ple-criteria decision analysis (MCDA)  could deal with 
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some limitations associated with single evaluation-based 
approaches when informing decision makers who require a 
range of information (not just related to VfM analyses) [144, 
145], with good practice guidance of emerging methodolo-
gies [146]. Edwards and McIntosh [35] discuss a method 
called “programme budgeting and marginal analysis” for 
economic evaluation and prioritisation between public health 
interventions. They suggest programme budgeting and mar-
ginal analysis is an example of multiple-criteria decision 
analysis and describe steps for its use, but as we are not 
familiar with the approach, we suggest the interested reader 
refer to Edwards and McIntosh [35]. Some authors have 
called for the application of realist evaluation methodologies 
[147] to better explain cost-efectiveness mechanisms within 
more “explanatory economic evaluations”. Anderson and 
Hardwick [147] describe the premise, comparing aspects of 
both realist evaluations and economic evaluations. Although 
we approve of the idea of more explanatory economic evalu-
ations, we believe the practical application and understand-
ing of such methodology to inform decision-making is in 
its early days.
It is important to note that even as part of NICE-based 
decision-making, there is a range of evidence produced 
(e.g. via non-randomised studies) that requires appropri-
ate methodologies that are not always taken into account. 
A review of NICE appraisals of pharmaceuticals (2000–16) 
by Anderson et al. [148] found variations in establishing 
comparative clinical efectiveness. Of 489 individual phar-
maceutical technologies assessed by NICE, 22 (4%) used 
non-RCT data to estimate comparative clinical efectiveness, 
with the methods for establishing external controls includ-
ing: 13 (59%) used published trials, 6 (27%) used observa-
tional data, 2 (9%) used expert opinion and 1 (5%) used a 
responder vs non-responder analysis. Only ive (23%) used 
a regression model to adjust for covariates, indicating that 
fundamental statistical methodology is missing even from 
evidence presented to NICE. Interestingly, the authors did 
not observe a notable diference in the proportion of phar-
maceutical technologies that received a positive recommen-
dation from NICE based on RCT or non-RCT data (83% vs 
86%). This suggests that even NICE recognises the need to 
use evidence from non-randomised study designs to inform 
decision-making, although the quality of such evidence still 
requires substantial scrutiny and appropriate statistical meth-
odology. For an example of a HTA that uses considerable 
evidence from single-arm trials using statistical comparator 
techniques, see Llewellyn et al. [149].
10  Conclusions
The time and budgetary restrictions placed on decision mak-
ers might mean that service evaluations are required as a 
vehicle for producing VfM evidence. As such evidence tends 
not to be peer reviewed and without formal guidance related 
to VfM analyses for service evaluations, there is the oppor-
tunity for sub-optimal analyses to be carried out. Although 
NICE and other guidance speciic to economic evaluations 
might not perfectly it these analyses to inform all decision 
makers, there are some fundamental aspects that should 
be taken into account including study design, data collec-
tion methods and sources, statistical methods and reporting 
standards. The use of study designs and statistical meth-
ods to account for confounding factors and potential biases, 
and methods to control and report on uncertainty around 
estimates and opportunity costs, are important aspects to 
consider. In terms of costs, even if considered outside the 
scope of the decision maker, related future costs should be 
included in the evaluation alongside intervention costs to 
account for potential opportunity costs in a care system that 
obtains its funding from the same overall care budget. In 
terms of relevant outcomes and associated VfM method, 
although alternative VfM analyses than CUA might be con-
sidered more appropriate or practical to use, CUA should 
be given priority. Alternative methods could then be ration-
alised, but still reported to current standards expected from 
using the CHEERS checklist. Accounting for the time hori-
zon of the decision problem is also important, which for 
longer time horizons could be accounted for using statistical 
and/or modelling-based methods. However, it is important 
to note that for some decision makers, the time horizon of 
interest may be more immediate short-term gains (i.e. over 
1 year) than longer term planning. We suggest that the time 
horizon over which all costs and efects relevant to the deci-
sion problem occur should be considered for the evaluation, 
with estimates reported over a relevant short (e.g. 1 year) 
and long term (e.g. 20 years). Value of information methods 
can then be used to monetarise the decision uncertainty over 
the relevant time horizons.
Acknowledgements We thank all members of the National Institute 
for Health Research Applied Research Collaboration Yorkshire and 
Humber (NIHR ARC YH) Health Economics, Evaluation and Equal-
ity Theme, at the University of York and University of Sheield. This 
includes members of the previous NIHR Collaboration for Leadership 
in Applied Health Research and Care YH (NIHR CLAHRC YH) Health 
Economics and Outcome Measurement Theme. The writing team and 
idea for this article were partly conceived based on the work conducted 
as part of the CLAHRC, which continues as part of the ARC. We 
also thank all organisers, presenters and participants at the CLAHRC-
funded Interventional Studies as Service Evaluations Workshop that 
took place in Sheield, UK, in June 2019. Aspects of this article were 
presented at that workshop, which allowed us to reine the content to 
address the thoughts and concerns provided by the researchers and 
Non-Randomised Value for Money Analyses
commissioners in attendance. We also thank The Academic Health 
Economists’ Blog (https ://ahebl og.com/) who through their weekly 
round-ups have provided us with some up-to-date research papers that 
we read and then referenced within the article.
Author Contributions All authors contributed to the idea about the 
content of the article. All authors have provided written contributions 
to the paper, including edits to drafts and the inal version. MF con-
ceived the original idea for the paper, then led the writing of the overall 
manuscript including the inal editing and formatting. JL and GR pro-
vided expert oversight and contributed throughout the manuscript. All 
authors act as guarantors for the content of the article.
Compliance with Ethical Standards 
Funding The writing of the article was part-funded by the National 
Institute for Health Research Applied Research Collaboration York-
shire and Humber (https ://www.arc-yh.nihr.ac.uk) and other funding 
organisations. The views expressed in this publication are those of 
the author(s) and not necessarily those of the National Institute for 
Health Research or the Department of Health and Social Care. The 
funding agreement ensured the authors’ independence in developing 
the purview of the manuscript and the writing and publishing of the 
manuscript.
Conflict of Interest Matthew Franklin, James Lomas and Gerry Rich-
ardson have no conlicts of interest that are directly relevant to the con-
tent of this article.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative 
Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons 
licence and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder.To view a copy of this licence, visit 
http://creat iveco mmons .org/licen ses/by-nc/4.0/.
References
 1. Akobeng AK. Principles of evidence based medicine. Arch Dis 
Child. 2005;90(8):837–40.
 2. Hunink MM, Weinstein MC, Wittenberg E, Drummond MF, 
Pliskin JS, Wong JB, et al. Decision making in health and medi-
cine: integrating evidence and values. Cambridge: Cambridge 
University Press; 2014.
 3. National Institute for Health and Care Excellence. Guide to the 
methods of technology appraisal. London: 2013.
 4. Rowen D, Zouraq IA, Chevrou-Severac H, van Hout B. Interna-
tional regulations and recommendations for utility data for health 
technology assessment. Pharmacoeconomics. 2017;35(1):11–9.
 5. Sculpher M, Palmer S. After 20 years of using economic evalua-
tion, should NICE be considered a methods innovator? Pharma-
coeconomics. 2020;38(3):247–57.
 6. Akobeng A. Understanding randomised controlled trials. Arch 
Dis Child. 2005;90(8):840–4.
 7. Research Ethics Service. Deining research. 2017. https ://www.
hra-decis ionto ols.org.uk/resea rch/docs/Dein ingRe searc hTabl 
e_Oct20 17-1.pdf. Accessed 22 Feb 2019.
 8. Petrou S. Rationale and methodology for trial-based economic 
evaluation. Clin Invest. 2012;2(12):1191–200.
 9. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither 
trial-based economic evaluation for health care decision making? 
Health Econ. 2006;15(7):677–87.
 10. Gevers S. Medical research involving human subjects: towards an 
international legal framework. Eur J Health Law. 2001;8:293–8.
 11. Hunter D. Efficiency and the proposed reforms to the NHS 
research ethics system. J Med Ethics. 2007;33(11):651–4.
 12. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, 
observational studies, and the hierarchy of research designs. N 
Engl J Med. 2000;342(25):1887–922.
 13. Frieden TR. Evidence for health decision making: beyond rand-
omized, controlled trials. N Engl J Med. 2017;377(5):465–75.
 14. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the 
gold standard: lessons from the history of RCTs. N Engl J Med. 
2016;374(22):2175–81.
 15. Chavez-MacGregor M, Giordano SH. Randomized clinical tri-
als and observational studies: is there a battle? J Clin Oncol. 
2016;34(8):772–3.
 16. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in 
therapeutical trials. J Clin Epidemiol. 2009;62(5):499–505.
 17. Spieth PM, Kubasch AS, Penzlin AI, Illigens BM-W, Barlinn K, 
Siepmann T. Randomized controlled trials: a matter of design. 
Neuropsychiatr Dis Treat. 2016;12:1341–9.
 18. Legislation.gov.uk. Health and Social Care Act 2012. 2012. 
https ://www.legis latio n.gov.uk/ukpga /2012/7/conte nts/enact ed. 
Accessed 5 May 2019.
 19. NHS England. NHS England Test Beds Programme: evaluation 
learning from Wave 1. 2018. https ://www.engla nd.nhs.uk/wp-
conte nt/uploa ds/2018/11/test-beds-progr amme-evalu ation -learn 
ing-from-wave-1.pdf. Accessed 17 Oct 2019.
 20. Van den Broucke S. Implementing health in all policies post 
Helsinki 2013: why, what, who and how. Health Promot Int. 
2013;28(3):281–4.
 21. World Health Organization. Health in all policies: Helsinki state-
ment. Framework for country action. Helsinki; 2014: Report No. 
9241506903.
 22. Davies SC, Walley T, Smye S, Cotterill L, Whitty CJ. The 
NIHR at 10: transforming clinical research. Clin Med. 
2016;16(6):501–2.
 23. Rovithis D. Do health economic evaluations using observational 
data provide reliable assessment of treatment efects? Health 
Econ Rev. 2013;3(1):21.
 24. World Medical Association. World Medical Association Declara-
tion of Helsinki: ethical principles for medical research involving 
human subjects. JAMA. 2013;310(20):2191–4.
 25. NHS HRA. Research Ethics Committee: standard operating 
procedures (update: March 2020). 2020. https ://www.hra.nhs.
uk/about -us/commi ttees -and-servi ces/res-and-recs/resea rch-ethic 
s-commi ttee-stand ard-opera ting-proce dures /. Accessed 9 Mar 
2020.
 26. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Tor-
rance GW. Methods for the economic evaluation of health care 
programmes. 4th ed. Oxford: Oxford University Press; 2015.
 27. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde 
S, et al. Methods for the estimation of the National Institute for 
Health and Care Excellence cost-efectiveness threshold. Health 
Technol Assess. 2015;19(14):1–503.
 28. Franklin M, Lomas J, Walker S, Young T. An educational review 
about using cost data for the purpose of cost-efectiveness analy-
sis. Pharmacoeconomics. 2019;37(5):631–43.
 M. Franklin et al.
 29. Booth N. On value frameworks and opportunity costs in health 
technology assessment. Int J Technol Assess Health Care. 
2019;35(5):367–72.
 30. Eddama O, Coast J. A systematic review of the use of eco-
nomic evaluation in local decision-making. Health Policy. 
2008;86(2–3):129–41.
 31. Eddama O, Coast J. Use of economic evaluation in local health 
care decision-making in England: a qualitative investigation. 
Health Policy. 2009;89(3):261–70.
 32. Department of Health and Social Care. The NHS constitution 
for England. 2015. https ://www.gov.uk/gover nment /publi catio ns/
the-nhs-const ituti on-for-engla nd/the-nhs-const ituti on-for-engla 
nd. Accessed 9 Mar 2020.
 33. Sutton M, Garield-Birkbeck S, Martin G, Meacock R, Morris 
S, Sculpher M, et al. Economic analysis of service and delivery 
interventions in health care. Health Serv Deliv Res. 2018;4:16. 
https ://doi.org/10.3310/hsdr0 6050.
 34. Kristensen FB, Husereau D, Huić M, Drummond M, Berger ML, 
Bond K, et al. Identifying the need for good practices in health 
technology assessment: summary of the ISPOR HTA Council 
Working Group Report on Good Practices in HTA. Value Health. 
2019;22(1):13–20.
 35. Edwards RT, McIntosh E. Applied health economics for public 
health practice and research. 2019.
 36. Weatherly H, Drummond M, Claxton K, Cookson R, Ferguson 
B, Godfrey C, et al. Methods for assessing the cost-efectiveness 
of public health interventions: key challenges and recommenda-
tions. Health Policy. 2009;93(2–3):85–92.
 37. Edwards RT, Charles JM, Lloyd-Williams H. Public health 
economics: a systematic review of guidance for the economic 
evaluation of public health interventions and discussion of key 
methodological issues. BMC Public Health. 2013;13(1):1001.
 38. Schafer SK, West P, Towse A, Henshall C, Mestre-Ferrandiz 
J, Masterton R, et al. Assessing the value of new antibiotics: 
additional elements of value for health technology assessment 
decisions. London: The Oice of Health Economics; 2017.
 39. Schaafsma JD, van der Graaf Y, Rinkel GJ, Buskens E. Deci-
sion analysis to complete diagnostic research by closing the gap 
between test characteristics and cost-efectiveness. J Clin Epide-
miol. 2009;62(12):1248–52.
 40. Drummond M, Griffin A, Tarricone R. Economic evalua-
tion for devices and drugs: same or diferent? Value Health. 
2009;12(4):402–4.
 41. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the 
health economic evaluation of genomic technologies. Pharma-
cogenomics. 2013;14(15):1833–47.
 42. McNamee P, Murray E, Kelly MP, Bojke L, Chilcott J, Fischer 
A, et al. Designing and undertaking a health economics study of 
digital health interventions. Am J Prev Med. 2016;51(5):852–60.
 43. Bojke L, Schmitt L, Lomas J, Richardson G, Weatherly H. Eco-
nomic evaluation of environmental interventions: relections on 
methodological challenges and developments. Int J Environ Res 
Public Health. 2018;15(11):2459.
 44. Meacock R. Methods for the economic evaluation of changes 
to the organisation and delivery of health services: principal 
challenges and recommendations. Health Econ Policy Law. 
2019;14(1):119–34.
 45. Briggs AH, O’Brien BJ. The death of cost-minimization analy-
sis? Health Econ. 2001;10(2):179–84.
 46. NICE Decision Support Unit (DSU). Cost minimisation. 2019. 
https ://niced su.org.uk/cost-minim isati on/. Accessed 16 Dec 
2019.
 47. Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of 
cost-consequence analysis in healthcare decision-making. Phar-
macoeconomics. 1998;13(3):277–88.
 48. Sullivan SD, Mauskopf JA, Augustovski F, Caro JJ, Lee KM, 
Minchin M, et al. Budget impact analysis: principles of good 
practice: report of the ISPOR 2012 Budget Impact Analysis 
Good Practice II Task Force. Value Health. 2014;17(1):5–14.
 49. National Institute for Health and Care Excellence (NICE). Medi-
cal technologies evaluation programme methods guide. London: 
National Institute for Health and Care Excellence (NICE); 2017.
 50. Optimity Advisors. Community engagement: approaches to 
improve health and reduce health inequalities: cost-consequence 
analysis. National Institute for Health and Care Excellence 
(NICE); 2016.
 51. Williams I, McIver S, Moore D, Bryan S. The use of economic 
evaluations in NHS decision-making: a review and empirical 
investigation. Health Technol Assess. 2008;12(7):1–175.
 52. Loomes G, McKenzie L. The use of QALYs in health care deci-
sion making. Soc Sci Med. 1989;28(4):299–308.
 53. NICE. Budget impact test. 2017; https ://www.nice.org.uk/about 
/what-we-do/our-progr ammes /nice-guida nce/nice-techn ology 
-appra isal-guida nce/budge t-impac t-test. Accessed 1 Apr 2020.
 54. NICE. Evidence standards for digital health technologies. ; 2019.
 55. York Health Economics Consortium (YHEC). National Institute 
for Health and Care Excellence evidence standards framework 
for digital health technologies: cost consequences and budget 
impact analyses and data sources. England: York; 2019.
 56. Masters R, Anwar E, Collins B, Cookson R, Capewell S. Return 
on investment of public health interventions: a systematic review. 
J Epidemiol Commun Health. 2017;71(8):827–34.
 57. NICE. Return on investment tools: beta versions. 2019. https 
://www.nice.org.uk/about /what-we-do/into-pract ice/retur n-on-
inves tment -tools . Accessed 1 Apr 2020.
 58. Public Health England (PHE). Health economics: a guide for 
public health teams. 2018. https ://www.gov.uk/guida nce/healt 
h-econo mics-a-guide -for-publi c-healt h-teams #the-cost-effec 
tiven ess-of-speci ic-topic -areas . Accessed 1 Apr 2020.
 59. Nicholls J, Mackenzie S, Somers A. Measuring real value: a DIY 
guide to social return on investment. London: New Economics 
Foundation; 2007.
 60. Social Value UK. Global value exchange. 2019. https ://www.
socia lvalu euk.org/resou rces/globa l-value -excha nge/. Accessed 
17 Oct 2019.
 61. Millar R, Hall K. Social return on investment (SROI) and 
performance measurement: the opportunities and barriers for 
social enterprises in health and social care. Public Manag Rev. 
2013;15(6):923–41.
 62. Culyer AJ. Cost, context, and decisions in health economics and 
health technology assessment. Int J Technol Assess Health Care. 
2018;34(5):434–41.
 63. de Vries LM, van Baal PH, Brouwer WB. Future costs in cost-
efectiveness analyses: past, present, future. Pharmacoeconomics. 
2019;37(2):119–30.
 64. Grima DT, Bernard LM, Dunn ES, McFarlane PA, Men-
delssohn DC. Cost-effectiveness analysis of therapies for 
chronic kidney disease patients on dialysis. Pharmacoeconom-
ics. 2012;30(11):981–9.
 65. van Baal P, Meltzer D, Brouwer W. Pharmacoeconomic 
guidelines should prescribe inclusion of indirect medi-
cal costs! A response to Grima et  al. Pharmacoeconomics. 
2013;31(5):369–73.
 66. Ten JB. arguments for a societal perspective in the eco-
nomic evaluation of medical innovations. Eur J Health Econ. 
2009;10(4):357–9.
 67. Walker S, Gri n S, Asaria M, Tsuchiya A, Sculpher M. Striving 
for a societal perspective: a framework for economic evaluations 
when costs and efects fall on multiple sectors and decision mak-
ers. Appl Health Econ Health Policy. 2019;17(5):577–90.
Non-Randomised Value for Money Analyses
 68. Franklin M, Thorn J. Self-reported and routinely collected elec-
tronic healthcare resource-use data for trial-based economic 
evaluations: the current state of play in England and considera-
tions for the future. BMC Med Res Methodol. 2019;19(1):8.
 69. Whyte S, Dixon S, Faria R, Walker S, Palmer S, Sculpher M, 
et al. Estimating the cost-efectiveness of implementation: is suf-
icient evidence available? Value Health. 2016;19(2):138–44.
 70. Hoomans T, Evers SM, Ament AJ, Hübben MW, Van Der Wei-
jden T, Grimshaw JM, et al. The methodological quality of 
economic evaluations of guideline implementation into clinical 
practice: a systematic review of empiric studies. Value Health. 
2007;10(4):305–16.
 71. Vale L, Thomas R, MacLennan G, Grimshaw J. Systematic 
review of economic evaluations and cost analyses of guideline 
implementation strategies. Eur J Health Econ. 2007;8(2):111–21.
 72. Hoomans T, Severens JL. Economic evaluation of implementa-
tion strategies in health care. Implement Sci. 2014;9:168.
 73. CPRD. Clinical practice research datalink. 2019. https ://www.
cprd.com/. Accessed 16 May 2019.
 74. NHS Digital. Secondary uses service (SUS). 2019. https ://digit 
al.nhs.uk/servi ces/secon dary-uses-servi ce-sus. Accessed 17 Oct 
2019.
 75. Franklin M, Berdunov V, Edmans J, Conroy S, Gladman J, Tana-
jewski L, et al. Identifying patient-level health and social care 
costs for older adults discharged from acute medical units in 
England. Age Ageing. 2014;43(5):703–7.
 76. Franklin M, Davis S, Horspool M, Kua WS, Julious S. Economic 
evaluations alongside eicient study designs using large observa-
tional datasets: the PLEASANT trial case study. Pharmacoeco-
nomics. 2017;35(5):561–73.
 77. Rees A, Paisley S, Brazier J, Cantrell A. Development of 
the Scharr HUD (Health Utilities Database). Value Health. 
2013;16:A580. https ://doi.org/10.1016/j.jval.2013.08.1585.
 78. Longworth L, Rowen D. NICE DSU technical support document 
10: the use of mapping methods to estimate health state utility 
values. Sheield: University of Sheield; 2011.
 79. Mukuria C, Rowen D, Harnan S, Rawdin A, Wong R, Ara R, 
et al. An updated systematic review of studies mapping (or cross-
walking) measures of health-related quality of life to generic 
preference-based measures to generate utility values. Appl 
Health Econ Health Policy. 2019;17(3):295–313.
 80. Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal 
of studies mapping from quality of life or clinical measures to 
EQ-5D: an online database and application of the MAPS state-
ment. Health Qual Life Outcomes. 2018;16:31.
 81. Hinde S, Bojke L, Richardson G. Understanding and addressing 
the challenges of conducting quantitative evaluation at a local 
level: a worked example of the available approaches. BMJ Open. 
2019;9(11):e029830.
 82. Coggon D, Rose G, Barker D. Epidemiology for the uninitiated, 
4th ed. BMJ; 1997. Accessed 2019.
 83. Dekkers OM, Egger M, Altman DG, Vandenbroucke JP. Dis-
tinguishing case series from cohort studies. Ann Intern Med. 
2012;156(1):37–40.
 84. Goodacre S. Uncontrolled before-after studies: discouraged by 
Cochrane and the EMJ. Emerg Med J. 2015;32(7):507–8.
 85. Sacks H, Chalmers TC, Smith H. Randomized versus historical 
controls for clinical trials. Am J Med. 1982;72(2):233–40.
 86. Grimes DA, Schulz KF. Descriptive studies: what they can and 
cannot do. Lancet. 2002;359(9301):145–9.
 87. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. 
Evidence of bias in estimates of inluenza vaccine efectiveness 
in seniors. Int J Epidemiol. 2006;35(2):337–44.
 88. Deidda M, Geue C, Kreif N, Dundas R, McIntosh E. A frame-
work for conducting economic evaluations alongside natural 
experiments. Soc Sci Med. 2019;220:353–61.
 89. Last JM, Spasof RA, Harris SS, Thuriaux MC. A dictionary of 
epidemiology. New York: International Epidemiological Asso-
ciation, Inc; 2001.
 90. Faria R, Alava MH, Manca A, Wailoo AJ. NICE Decision Sup-
port Unit (DSU) Technical Support Document (TSD) 17: the use 
of observational data to inform estimates of treatment efective-
ness in technology appraisal: methods for comparative individual 
patient data. Sheield: National Institute for Health and Care 
Excellence (NICE); 2015.
 91. Bell H, Wailoo AJ, Hernandez M, Grieve R, Faria R, Gibson 
L, et al. NICE Decision Support Unit (DSU) Technical Support 
Document (TSD): the use of real world data for the estimation of 
treatment efects in NICE decision making. Sheield: National 
Institute for Health and Care Excellence (NICE); 2016.
 92. Manca A, Austin PC. Using propensity score methods to analyse 
individual patient level cost efectiveness data from observational 
studies. York: The University of York; 2008.
 93. Kreif N, Grieve R, Radice R, Sekhon JS. Regression-adjusted 
matching and double-robust methods for estimating average 
treatment efects in health economic evaluation. Health Serv 
Outcomes Res Methodol. 2013;13(2–4):174–202.
 94. Crown WH. Propensity-score matching in economic analyses: 
comparison with regression models, instrumental variables, 
residual inclusion, diferences-in-diferences, and decomposi-
tion methods. Appl Health Econ Health Policy. 2014;12(1):7–8.
 95. Desai RJ, Franklin JM. Alternative approaches for confound-
ing adjustment in observational studies using weighting based 
on the propensity score: a primer for practitioners. BMJ. 
2019;367:l5657.
 96. Franklin M, Wailoo A, Dayer MJ, Jones S, Prendergast B, Bad-
dour LM, et al. The cost-efectiveness of antibiotic prophy-
laxis for patients at risk of infective endocarditis. Circulation. 
2016;134(20):1568–78.
 97. Bernal JL, Cummins S, Gasparrini A. Interrupted time series 
regression for the evaluation of public health interventions: a 
tutorial. Int J Epidemiol. 2017;46(1):348–55.
 98. Hunter RM, Baio G, Butt T, Morris S, Round J, Freemantle 
N. An educational review of the statistical issues in analys-
ing utility data for cost-utility analysis. Pharmacoeconomics. 
2015;33(4):355–66.
 99. Lewis JA. Statistical principles for clinical trials (ICH E9): 
an introductory note on an international guideline. Stat Med. 
1999;18(15):1903–42.
 100. Briggs A, Gray A. Handling uncertainty when performing eco-
nomic evaluation of healthcare interventions. Health Technol 
Assess. 1999;3(2):1–134.
 101. Culyer AJ. Cost-efectiveness thresholds in health care: a book-
shelf guide to their meaning and use. Health Econ Policy Law. 
2016;11(4):415–32.
 102. McCabe C, Claxton K, Culyer AJ. The NICE cost-efectiveness 
threshold. Pharmacoeconomics. 2008;26(9):733–44.
 103. Latimer NR. Survival analysis for economic evaluations along-
side clinical trials: extrapolation with patient-level data: incon-
sistencies, limitations, and a practical guide. Med Decis Mak. 
2013;33(6):743–54.
 104. Young TA. Estimating mean total costs in the presence of censor-
ing. Pharmacoeconomics. 2005;23(12):1229–422.
 105. Willan AR, Lin D, Manca A. Regression methods for 
cost-effectiveness analysis with censored data. Stat Med. 
2005;24(1):131–45.
 106. Wijeysundera HC, Wang X, Tomlinson G, Ko DT, Krahn MD. 
Techniques for estimating health care costs with censored data: 
an overview for the health services researcher. Clinicoecon Out-
comes Res. 2012;4:145–55.
 107. Briggs A, Sculpher M, Claxton K. Decision modelling for health 
economic evaluation. Oxford: Oxford University Press; 2006.
 M. Franklin et al.
 108. Franklin M, Hunter RM. A modelling-based economic evalua-
tion of primary-care-based fall-risk screening followed by fall-
prevention intervention: a cohort-based Markov model stratiied 
by older age groups. Age Ageing. 2019;49(1):57–66.
 109. Hunter RM, Fulop NJ, Boaden RJ, McKevitt C, Perry C, Ram-
say AI, et al. The potential role of cost-utility analysis in the 
decision to implement major system change in acute stroke ser-
vices in metropolitan areas in England. Health Res Policy Syst. 
2018;16(1):23.
 110. Jackson C, Presanis A, Conti S, De Angelis D. Value of informa-
tion: Sensitivity analysis and research design in Bayesian evi-
dence synthesis. J Am Stat Assoc. 2019;114(528):1436–49.
 111. Heath A, Manolopoulou I, Baio G. A review of methods for 
analysis of the expected value of information. Med Decis Mak-
ing. 2017;37(7):747–58.
 112. Strong M, Oakley JE, Brennan A. Estimating multi-parameter 
partial expected value of perfect information from a probabil-
istic sensitivity analysis sample: a non-parametric regression 
approach. Med Decis Making. 2014;34(3):311–26.
 113. Strong M, Oakley JE, Brennan A, Breeze P. Estimating the 
expected value of sample information using the probabilistic sen-
sitivity analysis sample: a fast, nonparametric regression-based 
method. Med Decis Mak. 2015;35(5):570–83.
 114. Wilson EC. A practical guide to value of information analysis. 
Pharmacoeconomics. 2015;33(2):105–21.
 115. Rothery C, Strong M, Koijberg H, Basu A, Ghabri S, Knies 
S, Murray JF, Schmidler GDS, Steuten L, Fenwick E. Value of 
information analytical methods: report 2 of the ISPOR Value of 
information analysis emerging good practices task force. Value 
Health. 2020;23(3):277–86.
 116. Cox M, O’Connor C, Biggs K, Hind D, Bortolami O, Franklin 
M, et al. The feasibility of early pulmonary rehabilitation and 
activity after COPD exacerbations: external pilot randomised 
controlled trial, qualitative case study and exploratory economic 
evaluation. Health Technol Assess. 2018;22(11):1–204.
 117. NICE. NICE technology appraisal guidance. 2020. https ://www.
nice.org.uk/about /what-we-do/our-progr ammes /nice-guida nce/
nice-techn ology -appra isal-guida nce. Accessed 9 Mar 2020.
 118. Kaltenthaler E, Boland A, Carroll C, Dickson R, Fitzgerald 
P, Papaioannou D. Evidence Review Group approaches to the 
critical appraisal of manufacturer submissions for the NICE STA 
process: a mapping study and thematic analysis. Health Technol 
Assess. 2011;15(22):1–82, iii–iv.
 119. NICE. The principles that guide the development of NICE guid-
ance and standards. 2020. https ://www.nice.org.uk/about /who-
we-are/our-princ iples . Accessed 9 Mar 2020.
 120. World Health Organization. The role of local government in 
health: comparative experiences and major issues. Geneva: 
World Health Organization; 1997.
 121. Furber A. Should local government run the NHS? BMJ. 
2016;355:i5962.
 122. Cullis J, Jones P. Public inance and public choice. 2nd ed. New 
York: Oxford University Press; 1998.
 123. Pettitt D, Raza S, Naughton B, Roscoe A, Ramakrishnan A, Ali 
A, et al. The limitations of QALY: a literature review. J Stem Cell 
Res Ther. 2016;6:4.
 124. Brazier J, Tsuchiya A. Improving cross-sector comparisons: 
going beyond the health-related QALY. Appl Health Econ Health 
Policy. 2015;13(6):557–65.
 125. Kind P, Lafata JE, Matuszewski K, Raisch D. The use of QALYs 
in clinical and patient decision-making: issues and prospects. 
Value Health. 2009;12:S27–30.
 126. Asaria M, Gri n S, Cookson R. Distributional cost-efectiveness 
analysis: a tutorial. Med Decis Making. 2016;36(1):8–19.
 127. Asaria M, Griin S, Cookson R, Whyte S, Tappenden P. Distri-
butional cost-efectiveness analysis of health care programmes: 
a methodological case study of the UK bowel cancer screening 
programme. Health Econ. 2015;24(6):742–54.
 128. Dawkins BR, Mirelman AJ, Asaria M, Johansson KA, Cookson 
RA. Distributional cost-efectiveness analysis in low-and middle-
income countries: illustrative example of rotavirus vaccination 
in Ethiopia. Health Policy Plan. 2018;33(3):456–63.
 129. Barnsley P, Towse A, Sussex J. Critique of CHE research paper 
81: methods for the estimation of the NICE cost efectiveness 
threshold. London: Oice of Health Economics (OHE); 2013.
 130. Claxton K, Sculpher M. Response to the OHE critique of CHE 
Research Paper 81: University of York; 2017.
 131. Raftery J. NICE’s cost-efectiveness range: should it be lowered? 
Pharmacoeconomics. 2014;32:613–5.
 132. Lomas J, Claxton K, Martin S, Soares M. Resolving the “cost-
effective but unaffordable” paradox: estimating the health 
opportunity costs of nonmarginal budget impacts. Value Health. 
2018;21(3):266–75.
 133. Ochalek J, Lomas J, Claxton K. Estimating health opportunity 
costs in low-income and middle-income countries: a novel 
approach and evidence from cross-country data. BMJ Global 
Health. 2018;3(6):e000964.
 134. Love-Koh J, Cookson R, Claxton K, Griin S. Estimating social 
variation in the health efects of changes in health care expendi-
ture. Med Decis Mak. 2020;40(2):170–82.
 135. Lomas JR. Incorporating afordability concerns within cost-
efectiveness analysis for health technology assessment. Value 
Health. 2019;22(8):898–905.
 136. Bilinski A, Neumann P, Cohen J, Thorat T, McDaniel K, Salo-
mon JA. When cost-efective interventions are unafordable: Inte-
grating cost-efectiveness and budget impact in priority setting 
for global health programs. PLoS Med. 2017;14(10):e1002397.
 137. Charlton V, Littlejohns P, Kieslich K, Mitchell P, Rumbold B, 
Weae A, et al. Cost efective but unafordable: an emerging chal-
lenge for health systems. BMJ. 2017;22(356):j1402.
 138. Pearson SD. The ICER value framework: integrating cost efec-
tiveness and afordability in the assessment of health care value. 
Value Health. 2018;21(3):258–65.
 139. Detsky AS, Laupacis A. Relevance of cost-efectiveness analysis 
to clinicians and policy makers. JAMA. 2007;298(2):221–4.
 140. NIHR. Journals. https ://www.journ alsli brary .nihr.ac.uk/journ als/. 
Accessed 9 Mar 2020.
 141. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, 
Greenberg D, et al. Consolidated health economic evaluation 
reporting standards (CHEERS): explanation and elaboration: 
a report of the ISPOR health economic evaluation publication 
guidelines good reporting practices task force. Value Health. 
2013;16(2):231–50.
 142. Grieve R, Abrams K, Claxton K, Goldacre B, James N, Nicholl 
J, et  al. Cancer Drugs Fund requires further reform. BMJ. 
2016;354:i5090.
 143. Yeh RW, Valsdottir LR, Yeh MW, Shen C, Kramer DB, Strom 
JB, et  al. Parachute use to prevent death and major trauma 
when jumping from aircraft: randomized controlled trial. BMJ. 
2018;363:k5094.
 144. Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J. Assessing 
the value of healthcare interventions using multi-criteria deci-
sion analysis: a review of the literature. Pharmacoeconomics. 
2014;32(4):345–65.
 145. Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, 
et al. Multiple criteria decision analysis for health care decision 
making:an introduction: report 1 of the ISPOR MCDA Emerging 
Good Practices Task Force. Value Health. 2016;19(1):1–13.
 146. Marsh K, Izerman M, Thokala P, Baltussen R, Boysen M, Kaló 
Z, et al. Multiple criteria decision analysis for health care deci-
sion making: emerging good practices: report 2 of the ISPOR 
Non-Randomised Value for Money Analyses
MCDA Emerging Good Practices Task Force. Value Health. 
2016;19(2):125–37.
 147. Anderson R, Hardwick R. Realism and resources: towards 
more explanatory economic evaluation. Evaluation. 
2016;22(3):323–41.
 148. Anderson M, Naci H, Morrison D, Osipenko L, Mossialos E. A 
review of NICE appraisals of pharmaceuticals 2000–2016 found 
variation in establishing comparative clinical efectiveness. J Clin 
Epidemiol. 2019;105:50–9.
 149. Llewellyn A, Faria R, Woods B, Simmonds M, Lomas J, Woola-
cott N, et al. Daclatasvir for the treatment of chronic hepatitis C: 
a critique of the clinical and economic evidence. Pharmacoeco-
nomics. 2016;34(10):981–92.
